Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$270.33−0.86 (-0.32%)
Close on Nov 18, 2026Market cap $16.75BP/E 22.2Yield –
Ascendis Pharma A/S net income
Net income is the profit left for shareholders after every expense, interest and tax.
Ascendis Pharma A/S's net income for the twelve months ending Jun 30, 2026 was €741.76M. For fiscal 2025 it was -€228.03M. The highest annual figure on record is -€130.10M in fiscal 2018.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€228.03M | – |
| FY2024 | Dec 31, 2024 | -€378.08M | – |
| FY2023 | Dec 31, 2023 | -€481.45M | – |
| FY2022 | Dec 31, 2022 | -€583.19M | – |
| FY2021 | Dec 31, 2021 | -€383.58M | – |
| FY2020 | Dec 31, 2020 | -€418.96M | – |
| FY2019 | Dec 31, 2019 | -€218.02M | – |
| FY2018 | Dec 31, 2018 | -€130.10M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €206.97M | – |
| Q1 FY2026 | Mar 31, 2026 | €629.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -€33.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -€60.99M | – |
| Q2 FY2025 | Jun 30, 2025 | -€38.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -€94.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -€38.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -€99.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -€109.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -€131.04M | – |
| Q4 FY2023 | Dec 31, 2023 | -€86.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -€162.22M | – |
| Q2 FY2023 | Jun 30, 2023 | -€121.43M | – |
| Q1 FY2023 | Mar 31, 2023 | -€110.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -€207.42M | – |
| Q3 FY2022 | Sep 30, 2022 | -€168.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -€81.32M | – |
| Q1 FY2022 | Mar 31, 2022 | -€125.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -€106.06M | – |
| Q3 FY2021 | Sep 30, 2021 | -€80.35M | – |
| Q2 FY2021 | Jun 30, 2021 | -€134.37M | – |
| Q1 FY2021 | Mar 31, 2021 | -€62.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -€138.97M | – |
| Q3 FY2020 | Sep 30, 2020 | -€121.74M | – |
| Q2 FY2020 | Jun 30, 2020 | -€94.93M | – |
| Q1 FY2020 | Mar 31, 2020 | -€63.32M | – |
| Q4 FY2019 | Dec 31, 2019 | -€80.36M | – |
| Q3 FY2019 | Sep 30, 2019 | -€25.11M | – |
| Q2 FY2019 | Jun 30, 2019 | -€58.90M | – |
See a number that looks wrong?